Suven Life Sciences Ltd
NSE: SUVEN BSE: 530239
₹210.18
(7.19%)
Wed, 22 Apr 2026, 07:05 am
Market Cap51.66B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1989
- Suven Pharmaceuticals Limited was promoted by Mr. Jasti Venkateswarlu and Mrs. Jasti Sudha Rani.
- The company was incorporated as a Private Limited Company in the state of Andhra Pradesh.
1995
- The company was converted into a Public Limited Company.
2000
- The company entered into an agreement with NSDL and CDSL for dematerialisation of shares.
- The company bagged export orders of Rs 21 cr.
2001
- Borregaard Industries Ltd, Norway, acquired a 15 percent stake in the company.
2002
- An accident occurred at the company's Suryapet Unit.
- Pfizer Ltd and Suven Pharmaceuticals Ltd tied up with the Bombay College of Pharmacy to set up an academy for clinical excellence.
2003
- Borregaard Industries Ltd offloaded its entire 17.05 percent stake in Suven Life Sciences.
- Suven Life Sciences USA LLC acquired Synthon Chiragenics Corporation, New Jersey, USA.
2004
- Suven Life Sciences informed the stock exchanges that its shareholders approved the sub-division of equity shares into a face value of Rs 2 each.
- Suven Life Sciences' board of directors approved a preferential shares issue.
- Suven Life Sciences allotted 30 lakh equity shares of face value of Rs 2 each on a preferential basis to four investors.
- Two units of Suven Life got ISO confirmation.
2007
- The European Patent Office granted two patents to Suven, valid until June 2022.
- The company issued bonus shares in the ratio of 1:1.
- The company split its face value from Rs2 to Rs1.
2009
- Suven Life Sciences secured two U.S. patents relating to new chemical entities for treatment of disorders associated with neurodegenerative diseases.
- Suven Life Sciences announced that the European Patent Office issued 3 new patents for NCEs for the treatment of disorders associated with neurodegenerative diseases.
2010
- Suven secured two product patents in China and Russia.
- Suven Life Sciences secured a 5th Product Patent from the US patent office for their NCE to treat Central Nervous System.
- Suven Life Sciences bagged the eighth product patent from the European Patent Office for their NCE to treat Central Nervous System disorders.
- Suven Life Sciences secured three Australian patents on NCEs.
- Suven got two patents from the Japanese Patent Office for NCEs.
2011
- Suven's Unit-III received US FDA acceptance.
- Suven Life Sciences secured 7 Product Patents for their NCEs in several key markets.
- Suven Life Sciences bagged the 'Bio-Excellence Award' at Bangalore India Bio 2011.
- Suven Life Sciences secured 2 Product Patents for their NCEs in key markets.
- Suven Life Sciences bagged Pharmexcil's 'Gold Patent Award'.
2012
- Suven Life Sciences secured 3 Product Patents for their NCEs in Mexico and USA.
- Suven Life Sciences got 4 Product Patents in Japan, Australia, Europe and Eurasia.
- Suven Life Sciences bagged Pharmexcil's 'Platinum Patent Award'.
- Suven Life Sciences secured 5 Product Patents for their NCEs in China and Korea.
2013
- Suven Life Sciences bagged 4 Product Patents for their NCEs in China, Mexico and New Zealand.
- Suven Life secured three Product Patents for their NCEs in Canada and Eurasia.
- Suven Life secured two Product Patents for their NCEs in Europe.
- The company recommended a dividend of 30 paisa per equity share of face value of Re. 1.
2014
- Suven's Pashamylaram unit received US FDA acceptance.
- Suven Life Sciences bagged Pharmexcil's 'Gold Patent Award' for NCEs and 'Outstanding Export Performance Award' for Contract Research and Manufacturing.
- Suven Life Sciences was awarded Forbes Asia's 'Best Under A Billion' Award.
2015
- Suven initiated Multiple Ascending Dose studies in Phase 1 clinical Trial for their investigational compound SUVN-G3031.
- Suven Life Sciences bagged Pharmexcil's Gold Patent Award.
2016
- Suven Life Sciences got a product patent for NCEs.
- Suven Life Sciences secured two Product Patents in Europe and Israel.
2017
- Suven Life Sciences secured Product Patents in Canada and India.
- Suven Life Sciences secured Product Patents in Eurasia and Norway.
- Suven bags product patent for treatment of neuro diseases.
2018
- Suven Life Sciences secured Product Patents in Brazil and Eurasia.
- Suven Life Sciences secured Product Patents in Australia and Hong Kong.
2019
- Suven completed the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc.
- Suven Life Sciences secured Product Patents in Australia and Singapore.
2022
- The company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 54 per share.
2023
- Suven completed enrollment of patients to the phase-2 clinical study of SUVN-G3031 in US and Canada.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800